Mamoru Nanasato
Research Subjects
Mamoru Nanasato has a total of 377 co-authors. Here are the top co-authors by number of shared publications:
Itaru Takamisawa
6 shared publicationsToyoaki Murohara
Department Cardiology, Nagoya University Graduate School of Medicine , 65 Tsurumai-cho, showa-ku, Nagoya, Aichi 466-8560 , Japan
6 shared publicationsMitsuaki Isobe
5 shared publications- Ryosuke Higuchi
Department of Cardiology, Sakakibara Heart Institute
5 shared publications - Toyoaki Murohara
Nagoya University Graduate School of Medicine
5 shared publications - Atsushi Tanaka
Department of Cardiovascular Medicine, Saga University , 5-1-1 Nabeshima, Saga 849-8501
4 shared publications
Latest Publications
- Open Access
- 5 September 2026
- Published by Elsevier in JACC: Asia
- Vol. 6 (10) , 2348-2358
Temporal Trends and Outcomes in Low-Risk Patients Undergoing TAVI
- 5 September 2026
- Published by Elsevier in JACC: Asia
- Vol. 6 (10) , 2348-2358
Open AccessTemporal Trends and Outcomes in Low-Risk Patients Undergoing TAVI
- Open Access
- 27 August 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 10 (9)
The jailed balloon technique for preventing coronary obstruction in the high-risk transcatheter aortic valve-in-transcatheter aortic valve
- 27 August 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 10 (9)
Open AccessThe jailed balloon technique for preventing coronary obstruction in the high-risk transcatheter aortic valve-in-transcatheter aortic valve
- Open Access
- 27 August 2026
- Published by Elsevier in JACC: Asia
Optimization of Commissural Alignment Using an Anatomy-Tailored Method for a Supra-Annular Self-Expanding Transcatheter Heart Valve
- 27 August 2026
- Published by Elsevier in JACC: Asia
Open AccessOptimization of Commissural Alignment Using an Anatomy-Tailored Method for a Supra-Annular Self-Expanding Transcatheter Heart Valve
- Open Access
- 12 June 2026
- Published by Elsevier in JACC: Asia
- Vol. 6 (9) , 2066-2077
Cardiac Rehabilitation Improves Outcomes After Thoracic Aortic Aneurysm Repair
- 12 June 2026
- Published by Elsevier in JACC: Asia
- Vol. 6 (9) , 2066-2077
Open AccessCardiac Rehabilitation Improves Outcomes After Thoracic Aortic Aneurysm Repair
- Open Access
- 19 May 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (10) , e044105
Real‐World Outcomes of FFRangio‐Guided Treatment for Coronary Artery Disease in Acute Versus Chronic Coronary Syndromes
Background: The use of angiogram‐based fractional flow reserve technologies in routine clinical practice is increasing steadily. Available data suggest that it is associated with comparable clinical outcomes compared with wire‐based fractional flow reserve (FFR), but evidence is still limited, especially in patients with acute coronary syndromes (ACSs). The aim of this study was to examine the real‐world clinical outcomes of an angiogram based fractional flow reserve technology (FFRangio; CathWorks, Kfar‐Saba, Israel) to guide treatment for coronary artery disease in patients presenting with acute versus chronic coronary syndromes (CCSs). Methods: This is a retrospective, observational study. Our cohort included consecutive patients undergoing coronary angiography in 7 centers (Japan, 6; Israel, 1), whose treatment was guided by FFRangio between January 2021 and December 2023. The primary end point was 2‐year cumulative incidence of major adverse cardiac events, stratified by presentation (ACS/CCS) and treatment strategy (revascularization/deferral). Results: Overall, 2245 patients (ACS, 756; CCS, 1489) were included. Patients with ACS were younger and more likely to be diabetic. At 2 years, ACS presentation resulted in higher risk of major adverse cardiac events (9.8% versus 5.6%; HR, 1.80; P P =0.672) for treated patients, ACS presentation associated with increased risk for major adverse cardiac events (11.7% versus 7.3%; HR, 1.64; P <0.001). Conclusions: In a real‐world setting, FFRangio‐guided treatment yields 2‐year outcomes comparable with current data for wire‐based fractional flow reserve for both patients with ACS and patients with CCS. ACS presentation is associated with increased risk for major adverse cardiac events in patients undergoing FFRangio‐guided revascularization but not deferral. These results demonstrate the clinical utility of FFRangio‐guided treatment across the spectrum of coronary artery disease presentation excluding ST‐segment–elevation myocardial infarction. Registration: URL: https://clinicaltrials.gov/study/NCT05648396?term=FFRangio%20&viewType=Card&rank=3 ; Unique Identifier: NCT05648396.
- 19 May 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (10) , e044105
Open AccessReal‐World Outcomes of FFRangio‐Guided Treatment for Coronary Artery Disease in Acute Versus Chronic Coronary Syndromes
Background: The use of angiogram‐based fractional flow reserve technologies in routine clinical practice is increasing steadily. Available data suggest that it is associated with comparable clinical outcomes compared with wire‐based fractional flow reserve (FFR), but evidence is still limited, especially in patients with acute coronary syndromes (ACSs). The aim of this study was to examine the real‐world clinical outcomes of an angiogram based fractional flow reserve technology (FFRangio; CathWorks, Kfar‐Saba, Israel) to guide treatment for coronary artery disease in patients presenting with acute versus chronic coronary syndromes (CCSs). Methods: This is a retrospective, observational study. Our cohort included consecutive patients undergoing coronary angiography in 7 centers (Japan, 6; Israel, 1), whose treatment was guided by FFRangio between January 2021 and December 2023. The primary end point was 2‐year cumulative incidence of major adverse cardiac events, stratified by presentation (ACS/CCS) and treatment strategy (revascularization/deferral). Results: Overall, 2245 patients (ACS, 756; CCS, 1489) were included. Patients with ACS were younger and more likely to be diabetic. At 2 years, ACS presentation resulted in higher risk of major adverse cardiac events (9.8% versus 5.6%; HR, 1.80; P P =0.672) for treated patients, ACS presentation associated with increased risk for major adverse cardiac events (11.7% versus 7.3%; HR, 1.64; P <0.001). Conclusions: In a real‐world setting, FFRangio‐guided treatment yields 2‐year outcomes comparable with current data for wire‐based fractional flow reserve for both patients with ACS and patients with CCS. ACS presentation is associated with increased risk for major adverse cardiac events in patients undergoing FFRangio‐guided revascularization but not deferral. These results demonstrate the clinical utility of FFRangio‐guided treatment across the spectrum of coronary artery disease presentation excluding ST‐segment–elevation myocardial infarction. Registration: URL: https://clinicaltrials.gov/study/NCT05648396?term=FFRangio%20&viewType=Card&rank=3 ; Unique Identifier: NCT05648396.
- Open Access
- 14 February 2026
- Published by Elsevier in JACC: Advances
- Vol. 5 (3)
Outcomes After Repeat Alcohol Septal Ablation in Patients With Obstructive Hypertrophic Cardiomyopathy
- 14 February 2026
- Published by Elsevier in JACC: Advances
- Vol. 5 (3)
Open AccessOutcomes After Repeat Alcohol Septal Ablation in Patients With Obstructive Hypertrophic Cardiomyopathy
- 2 February 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Imaging
- Vol. 27 (4) , 721-732
Optical coherence tomography-guided stent optimization and clinical outcomes in all-comer patients with ST-elevation myocardial infarction
Aims: Although the advantages of intra-coronary imaging guidance in percutaneous coronary intervention (PCI) have been reported, the advantage of optical coherence tomography (OCT) guided PCI has not been elucidated in patients with ST-elevation myocardial infarction (STEMI). This study assessed the association between OCT findings after stent implantation and 1-year outcomes in an all-comer STEMI population. Methods and results: The ATLAS-OCT trial was a prospective, multicentre, single-arm study enrolling STEMI patients within 24 h of symptom onset. OCT-guided PCI was preferred when feasible. This analysis included patients with analysable post-PCI OCT images. The primary endpoint was target vessel failure (TVF; all-cause death, target vessel myocardial infarction [TVMI], or target vessel revascularization [TVR]). OCT images were analysed independently, and outcomes assessed at 12 months. Of 632 patients, 439 (69.5%) underwent OCT-guided stenting with final analysable imaging. Mean minimal stent area (MSA) and stent expansion (SE) were 6.21 ± 2.27 mm² and 76.8 ± 15.6%, respectively. Optimization criteria (MSA > 4.5 mm² and/or SE > 70%) were met in 87.7%. Suboptimal expansion was associated with higher TVF (20.4% vs. 8.1%; HR 2.57, 95% CI: 1.29–5.11), driven by TVMI and TVR. Each 1 mm² MSA decrease and 10% SE reduction increased TVF odds by 23% and 33%, respectively. Minor OCT findings were not significantly associated with outcomes. Conclusion: In STEMI, suboptimal MSA and SE determined by OCT were associated with higher adverse event risk. These findings support OCT-guided PCI optimization to improve outcomes and warrant further evaluation in randomized trials. Study Registration: University Hospital Medical Information Network Clinical Trials Registry of Japan (UMIN-CTR number: 000048590)
- 2 February 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Imaging
- Vol. 27 (4) , 721-732
Optical coherence tomography-guided stent optimization and clinical outcomes in all-comer patients with ST-elevation myocardial infarction
Aims: Although the advantages of intra-coronary imaging guidance in percutaneous coronary intervention (PCI) have been reported, the advantage of optical coherence tomography (OCT) guided PCI has not been elucidated in patients with ST-elevation myocardial infarction (STEMI). This study assessed the association between OCT findings after stent implantation and 1-year outcomes in an all-comer STEMI population. Methods and results: The ATLAS-OCT trial was a prospective, multicentre, single-arm study enrolling STEMI patients within 24 h of symptom onset. OCT-guided PCI was preferred when feasible. This analysis included patients with analysable post-PCI OCT images. The primary endpoint was target vessel failure (TVF; all-cause death, target vessel myocardial infarction [TVMI], or target vessel revascularization [TVR]). OCT images were analysed independently, and outcomes assessed at 12 months. Of 632 patients, 439 (69.5%) underwent OCT-guided stenting with final analysable imaging. Mean minimal stent area (MSA) and stent expansion (SE) were 6.21 ± 2.27 mm² and 76.8 ± 15.6%, respectively. Optimization criteria (MSA > 4.5 mm² and/or SE > 70%) were met in 87.7%. Suboptimal expansion was associated with higher TVF (20.4% vs. 8.1%; HR 2.57, 95% CI: 1.29–5.11), driven by TVMI and TVR. Each 1 mm² MSA decrease and 10% SE reduction increased TVF odds by 23% and 33%, respectively. Minor OCT findings were not significantly associated with outcomes. Conclusion: In STEMI, suboptimal MSA and SE determined by OCT were associated with higher adverse event risk. These findings support OCT-guided PCI optimization to improve outcomes and warrant further evaluation in randomized trials. Study Registration: University Hospital Medical Information Network Clinical Trials Registry of Japan (UMIN-CTR number: 000048590)
- Open Access
- 21 January 2026
- Published by Elsevier in JACC: Asia
- Vol. 6 (4) , 477-489
Effect of Device Size on Outcomes Following Left Atrial Appendage Closure in Borderline-Sized Anatomy
- 21 January 2026
- Published by Elsevier in JACC: Asia
- Vol. 6 (4) , 477-489
Open AccessEffect of Device Size on Outcomes Following Left Atrial Appendage Closure in Borderline-Sized Anatomy
- Open Access
- 6 January 2026
- Published by Elsevier in JACC: Asia
- Vol. 6 (1) , 80-90
Antithrombotic Therapy After Percutaneous Left Atrial Appendage Closure
- 6 January 2026
- Published by Elsevier in JACC: Asia
- Vol. 6 (1) , 80-90
Open AccessAntithrombotic Therapy After Percutaneous Left Atrial Appendage Closure